Replies to post #7346 on Theriva Biologics Inc (TOVX)

[Citrati]

While I understand the sentiment, raising capital to fund trials is also why companies are public.
SYN ended 2016 with cash on hand essentially equal to average of the previous 3 years.
About 20million shares per year is average for them, which would get it in the 130million O/S range.
Not unreasonable IMO given the potential market size.
Maybe they will get more friendly funding from RJ Kirk again.
Totally willing to wait this out and see how it comes together.
As always, I plan on taking profits on the way up, whatever the length of the move.
SYN